LivingGLP1
Study S003384

GLP-1 Inhibits Prandial Antro-duodeno-jejunal Motility in Humans: Native GLP-1 Compared With Analogue ROSE-010 in Vitro

ClinicalTrials.gov record

Registration

Registration
NCT02731664
Acronym
GLPMOT
Study type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Phase
PHASE1
Masking
SINGLE
Status
COMPLETED
Enrollment
12
Start
2012-09
Primary completion
2017-08
Lead sponsor
Uppsala University
Conditions
Functional Gastrointestinal Disorders
Interventions
BIOLOGICAL:GLP-1; BIOLOGICAL:Intravenous saline
Results posted
FALSE
Individual participant data sharing
YES

Registered primary outcomes

  • Motility index (measure of contraction amplitude x duration; area for mmHg x sec) [60 minutes]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0030366Glucagon-Like Peptide-1 Inhibits Prandial Gastrointestinal Motility Through Myenteric Neuronal Mechanisms in Humans.
Halim MA, The Journal of clinical endocrinology and metabolism
2018Other trialPMID 29177486DOIcites ClinicalTrials.gov:NCT02731664; registry reference DERIVED:29177486
R0027934Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis.
Edholm T, Neurogastroenterology and motility
2010Randomized trialPMID 20584260DOIregistry reference BACKGROUND:20584260
R0025883Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study.
Hellström PM, Alimentary pharmacology & therapeutics
2009Randomized trialPMID 18945254DOIregistry reference BACKGROUND:18945254